Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders
Authors:
- 1 June 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 29 (5) , 348-361
Abstract
Objective: To determine whether genetic variants in a pharmacokinetic gene (the number of CYP2C19 reduced function alleles [RFAs]), and in pharmacodynamic genes (HTR2A, SLC6A4, and GRIK4) influence sertraline tolerability and response in a cohort of pediatric patients with anxiety and depressive disorders. Methods: A retrospective analysis was performed using the electronic medical record data of 352 patients CYP2C19 genotyping. Additional genotyping and analysis of variants in HTR2A, SLC6A4, and GRIK4 were conducted for 249 patients. Multivariate regression models testing for associations with CYP2C19 were adjusted for concomitant use of interacting medications. Combinatorial classification and regression tree (CART) analyses containing all pharmacokinetic and pharmacodynamic genes and clinical factors were performed. Results: The maximum sertraline dose during the initial titration period of sertraline was inversely associated with the number of CYP2C19 RFAs and sertraline dose at 60 (p = 0.025) and 90 days (p = 0.025). HTR2A rs6313 was associated with sertraline dose (p = 0.011) and time to the average maximum sertraline dose (p = 0.039). Regarding efficacy, the number of CYP2C19 RFAs was not associated with the sertraline dose at the time of response (p = 0.22), whereas for the pharmacodynamic genes, only HTR2A rs6313 was associated with response dose (p = 0.022). An association was observed between predicted expression levels of SLC6A4 and the duration on sertraline (p = 0.025). Combinatorial CART and multivariate regression analyses implicated that pharmacodynamic genes and clinical factors influence the maximum sertraline dose and response dose. The total number of side effects was not associated with any of the variants tested. Conclusion: Both pharmacokinetic and pharmacodynamic factors, in addition to clinical and demographic components, influence sertraline dose, response, and tolerability, thereby necessitating further research to assess for the validity of these pharmacogenetic associations in children and adolescents.Keywords
This publication has 61 references indexed in Scilit:
- Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health’s Collaborative Center for Genomic StudiesTranslational Psychiatry, 2013
- Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain functionMolecular Psychiatry, 2012
- Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacyEuropean Neuropsychopharmacology, 2012
- Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major DepressionNeuropsychobiology, 2012
- Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteersBritish Journal of Clinical Pharmacology, 2010
- Polymorphisms in GRIK4, HTR2A, and FKBP5 Show Interactive Effects in Predicting Remission to Antidepressant TreatmentNeuropsychopharmacology, 2009
- Resequencing of serotonin-related genes and association of tagging SNPs to citalopram responsePharmacogenetics and Genomics, 2009
- Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood AnxietyNew England Journal of Medicine, 2008
- Serotonin Transporter Promoter Gain-of-Function Genotypes Are Linked to Obsessive-Compulsive DisorderThe American Journal of Human Genetics, 2006
- Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant TreatmentThe American Journal of Human Genetics, 2006